Rankings
▼
Calendar
FATE Q3 2018 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
FATE
Fate Therapeutics, Inc.
$142M
Q3 2018 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$1M
+0.0% YoY
Gross Profit
-$13M
-1229.1% margin
Operating Income
-$17M
-1626.9% margin
Net Income
-$17M
-1635.7% margin
EPS (Diluted)
$-0.31
QoQ Revenue Growth
-0.1%
Cash Flow
Operating Cash Flow
-$4M
Free Cash Flow
-$4M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$220M
Total Liabilities
$46M
Stockholders' Equity
$174M
Cash & Equivalents
$183M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$1M
$1M
+0.0%
Gross Profit
-$13M
-$8M
-67.0%
Operating Income
-$17M
-$10M
-61.4%
Net Income
-$17M
-$11M
-57.1%
← FY 2018
All Quarters
Q4 2018 →